"Over the last couple of years, biomedical science has made enormous strides in advancing human health and treating disease. It has become clear now that health is active, and disease evolves when abberated. New technology is therefore needed to observe biological processes unfolding in real-time within tissue context over extended periods of time.
Our vision at Vitroscope is to develop tomorrow’s technology to transform today’s life science research landscape in academia and industry."
"Vitroscope was started in 2019 based on 5 years of research at the Norwegian University of Science and Technology in collaboration with the University of Zurich.
The 2020/2021 pandemic and subsequent challenges with remote work further - as well as the urgency for more accurate early stage clinical research confirmed our AI-native approach. The future of life science lies in high-accuracy, vertically integrated data flow.
Since 2022, we are engaged in multiple exciting commercial collaborations to extend our AI-native measuring and control of perfusion & live imaging capabilities.
Recent advancements in science have begun to offer increasingly viable alternatives to animal testing. At the end of 2022, the approved FDA Modernization Act 2.0 allows companies to submit non-animal data using certain alternative technologies to demonstrate the safety and efficacy of investigational drugs prior to human trials. Vitroscope aims to provide one of those enabling technologies."
"We are an international and inclusive team with a passion for technology, biology, and creating impactful solutions at the interface between engineering and life. Some of us met through PhD studies, others through serendipity, others out of pure interest in technology - and we all connect through a deeply rooted curiosity about advancing active health and resolving disease."
joined Vitroscope in 2020. Experiencing chronic health issues, she joined Vitroscope with a mission: to leverage our technology to better understand her own body and to discover health treatments that promote high life quality and longevity. She holds a MSc in Biotechnology from NTNU Trondheim.
Therapeutic Area Lead Oncology at Charles River Laboratories
Associate Professor at Oxford University and the Rosalind Franklin Institute, leading the Biophysical Immunology Laboratory (www.bpi-oxford.com), as well as the Scientific Director of the Oxford-ZEISS Centre of Excellence.
Silicon Valley biotech veteran, advices Vitroscope on aspects of biomedical industry, key hires, strategies, and business model development.
Professor Magnar Bjørås is a Principle Investigator of the research group of Cellular responses to DNA damage at Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim and at Oslo University Hospital/University of Oslo.
Internationally experienced business consultant & angel investor.
Accomplished scientist, CEO, and entrepreneur turned investor.
Professor for early stage product development. Previously at Stanford and MIT.